Bank Of America Corp Clene Inc. Transaction History

Bank Of America Corp

$1.12 Trillion
Q2 2024

A detailed history of Bank Of America Corp transactions in Clene Inc. stock. As of the latest transaction made, Bank Of America Corp holds 772 shares of CLNN stock, worth $4,531. This represents 0.0% of its overall portfolio holdings.

Number of Shares

772

Previous 32,319 97.61%

Holding current value

$4,531

Previous $13,000 100.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$0.31 - $0.44 $9,779 - $13,880	-31,547 Reduced 97.61%	772 $0
Q1 2024 May 15, 2024	BUY	$0.28 - $0.53 $3,058 - $5,789	10,923 Added 51.05%	32,319 $13,000
Q4 2023 Feb 14, 2024	SELL	$0.26 - $0.55 $164 - $347	-631 Reduced 2.86%	21,396 $6,000
Q2 2023 Aug 14, 2023	BUY	$0.78 - $1.22 $15,989 - $25,008	20,499 Added 1341.56%	22,027 $19,000
Q1 2023 May 12, 2023	SELL	$0.95 - $1.62 $5,082 - $8,667	-5,350 Reduced 77.78%	1,528 $1,000
Q4 2022 Feb 10, 2023	BUY	$0.92 - $40.2 $27 - $1,206	30 Added 0.44%	6,878 $6,000
Q3 2022 Nov 14, 2022	BUY	$0.33 - $73.0 $249 - $55,261	757 Added 12.43%	6,848 $19,000
Q2 2022 Aug 12, 2022	SELL	$2.1 - $4.12 $120,090 - $235,606	-57,186 Reduced 90.37%	6,091 $15,000
Q1 2022 May 16, 2022	BUY	$2.42 - $4.42 $52,431 - $95,763	21,666 Added 52.07%	63,277 $249,000
Q4 2021 Feb 08, 2022	BUY	$3.95 - $7.53 $120,076 - $228,904	30,399 Added 271.13%	41,611 $170,000
Q3 2021 Nov 15, 2021	BUY	$6.83 - $13.58 $36,560 - $72,693	5,353 Added 91.36%	11,212 $77,000
Q2 2021 Sep 13, 2021	BUY	$6.98 - $13.33 $40,895 - $78,100	5,859 New	5,859 $66,000

Others Institutions Holding CLNN

# of Institutions

Shares Held

6.22M

Call Options Held

287K

Put Options Held

162K

View Full List

About Clene Inc.

Ticker CLNN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,502,000
Market Cap $373M
Description
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral scleros...

More about CLNN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.

Account

Bank Of America Corp Clene Inc. Transaction History